At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
Blood sampling and bone marrow analysisother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
sdAb-based Targeted Radionuclide Therapy of Multiple Myeloma: a Feasibility Study
In Brief
A clinical study evaluating Blood sampling and bone marrow analysis for Multiple Myeloma. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This study aims to show that antiidiotypic sdAb are a new, sensitive, specific and non-invasive tool for imaging and therapeutic purposes and provides a rationale for their clinical evaluation as a personalized treatment option for MM patients expressing surface paraprotein.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesBelgium
CollaboratorsStichting tegen Kanker
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartFeb 2019
First PostedMay 2019
Primary CompletionDec 2020
TodayJul 2026
First PostedMay 21, 2019
Enrollment StartFeb 12, 2019
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.1 years ago
Interventions
Blood sampling and bone marrow analysisother
Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)